Related Experiment Video
Updated: Feb 7, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
Andrea Sbrana1, Elisa Biasco2, Federico Paolieri3
1U.O. Oncologia Medica 2 Universitaria, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy andreasbrana89@gmail.com.
Background/Aim:
The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma.
Patients And Methods:
Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting.
Results:
In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04).
Conclusion:
Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.
Related Concept Videos
Long-term Depression
What is an Experiment?
Gene Therapy
Thomson's e/m Experiment
A particle with charge q, speed v, and mass m enters an area from the top, where the magnetic and electric fields are perpendicular both to the particle's motion and to one another. The magnetic...
Controls in Experiments
Randomized Experiments
Simple randomization
Simple...

